Policy Comment Letters

As part of its advocacy mission, the Society for Women's Health Research monitors the activities of the executive branch in the areas of women's health and research. At the request of various federal agencies, SWHR periodically submits public comment letters detailing its positions on issues pertaining to SWHR's public policy priorities.

2012

• SWHR Comments on FDA Guidance on the Evaluation of Sex Differences in Medical Device Clinical Studies (March 13, 2012)

2011

• SWHR Comments on New FDA Data Regulations (July 28, 2011)

• SWHR Comment Letter to IOM Pain Committee (April 4, 2011)

• SWHR Comments to FDA on HFCS (March 8, 2011)

• SWHR Comments to National Vaccine Advisory Committee (February 8, 2011)

• SWHR Comment on Pregnancy Drug Labeling (January 27, 2011)

• SWHR Comment on Tobacco Labels (January 11, 2011)

2010

• Comments submitted to FDA on the 501k Device Approval Process (October 4, 2010)

• Recommendations to the U.S. Preventive Services Task Force (August 26, 2010)

• Letter to HHS regarding 2010-2015 Strategic Plan (August 13, 2010)

• Appropriations Letter to Sebelius (July 15, 2010)

• Letter to Defense Advisory Committee on Women in the Services (DACOWITS) on Military Sexual Trauma (May 27, 2010)

• Comments Submitted on FDA NIH Collaboration (May 26, 2010)

• Comments Submitted on U.S. Preventive Services Task Force "I" statements (April 28, 2010)

• Comments Submitted regarding Comparative Effectiveness Research (Submitted to AHRQ March 30, 2010)

• Comments in Support of Changing the Definition of Human Embryonic Stem Cells (Submitted to NIH March 18, 2010)

2009

• Institute of Medicine- Comparative Effectiveness (July 31, 2009)

• Clinical Trials Comment Letter (February 27, 2009)

2008

• Pregnancy and Lactation Labeling Proposed Regulation (August 21, 2008)

• Possible FDA Approval of Thalidomide Product (August 15, 2008)

• NIDA Strategic Plan (February 5, 2008)

2007

• NIMH Draft Strategic Plan (December 20, 2007)

2005

• FDA Plan B Delay (August 2005)

• CMS Coverage with Evidence Development Comment Letter (June 6, 2005)

2004

• CMS Formulary Comment Letter (December 15, 2004)

• CMS Pass-Through Payments for New Tech Letter (December 9, 2004)

• CMS Med Tech Payment Letter (November 3, 2004)

• Letter to USP on Model MMA Drug Guidelines (September 16, 2004)

• Final HHS Comment Letter (August 23, 2004)

• FDA Comment Letter (July 21, 2004)